COMPASS THERAPEUTICS, INC. (CMPX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -81.08M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-81.08M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-75.17M | (m) | (m) | $56.30M | (m) | (m) |
| 2025-12-31 | $-72.84M | (m) | (m) | $55.97M | (m) | (m) |
| 2025-09-30 | $-71.42M | (m) | (m) | $55.34M | (m) | (m) |
| 2025-06-30 | $-67.84M | (m) | (m) | $51.12M | (m) | (m) |
| 2025-03-31 | $-61.82M | (m) | (m) | $45.87M | (m) | (m) |
| 2024-12-31 | $-56.63M | (m) | (m) | $42.34M | (m) | (m) |
| 2024-09-30 | $-55.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-55.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-53.42M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-50.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-47.86M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-48.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-44.18M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-41.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-41.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-35.03M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-81.72M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-81.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-76.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-79.94M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-29.32M | (m) | (m) | $16.04M | (m) | (m) |
| 2020-12-31 | $-27.81M | (m) | (m) | $14.90M | (m) | (m) |
| 2020-09-30 | $-14.05M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-5.09M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-32.10K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-35.52K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $-34.55K | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-35.18K | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-32.76K | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |